NEW YORK, NY / / February 11, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want ...

Crown Laboratories and its affiliate Reba Merger Sub will now pay for the shares, which will cost the company $314.6 million.

JOHNSON CITY, Tenn. - Crown Laboratories, Inc., a global skincare company, has finalized its acquisition of biotechnology ...

Crown Laboratories, a portfolio company of Hildred Capital, has acquired Revance Therapeutics, a Nashville-based provider of dermal fillers. No financial terms were disclosed. Crown is a Johnson City, ...

Analysts at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a research ...

Johnson City-based Crown Laboratories is now offering the public biotechnology company’s stockholders $3.65 per share of its ...

Securities maintained its Neutral rating on Revance Therapeutics (NASDAQ:RVNC) with a steady price target of $3.65, closely ...

Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock ...

Nashville-based aesthetics biotech company Revance Therapeutics announced Wednesday that a planned merging with Johnson City, ...

Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance ...

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...